Aptinyx Presents Preclinical and Phase 1 Clinical Data from NYX-2925 at the 20th Annual Meeting of the American Society for Experimental Neurotherapeutics
EVANSTON, Ill., March 8, 2018 /PRNewswire/ -- Aptinyx Inc., a clinical-stage biopharmaceutical company developing transformative therapies for challenging neurologic disorders, today announced they will present preclinical and early-stage clinical data from studies of the company's lead product candidate, NYX-2925, at the 20th Annual Meeting of the American Society for Experimental Neurotherapeutics, March 7-10, 2018 in Rockville, MD. The presentation features results from preclinical studies that further demonstrate efficacy and safety of NYX-2925, Aptinyx's novel modulator of the N-methyl-D-aspartate (NMDA) receptor, in several models of neuropathic pain. The presentation also includes Phase 1 clinical data outlining the safety, tolerability, and pharmacokinetics of NYX-2925 in healthy volunteers.
"NYX-2925 has consistently shown favorable safety and tolerability in both preclinical and clinical studies," said Torsten Madsen, M.D., Ph.D., chief medical officer of Aptinyx. "The Phase 1 data reinforce the drug's clean safety and tolerability profile and informed the doses we selected for our ongoing Phase 2 clinical study of NYX-2925 in neuropathic pain associated with diabetic peripheral neuropathy, as well as our exploratory study in fibromyalgia."
In several preclinical models of neuropathic pain, NYX-2925 demonstrated reproducible and dose-dependent analgesic activity. At doses well in excess of the analgesic dose levels, NYX-2925 did not have adverse effects in safety-pharmacology and toxicology studies. NYX-2925 had high oral bioavailability and the pharmacokinetics were reproducible and predictable across species.
In a Phase 1 clinical study assessing NYX-2925's safety, tolerability, and pharmacokinetics, once-daily oral dosing for seven days produced linear, dose-proportional pharmacokinetics and minimal accumulation in 84 healthy adult volunteers. NYX-2925 was generally well-tolerated, there were no serious adverse events reported, and no subjects discontinued due to adverse events. Additionally, evaluation of cerebrospinal fluid (CSF) samples from study participants confirmed that NYX-2925 crosses the blood-brain barrier. Drug concentrations in CSF were ample - approximately 6-9% of those measured in plasma - indicating that central nervous system exposure commensurate with preclinically efficacious doses can be achieved via oral dosing in humans.
Discovered by Aptinyx scientists leveraging the company's proprietary small-molecule chemistry platform, NYX-2925 is an oral, small-molecule NMDA receptor modulator. NYX-2925 binds to a novel site on the NMDA receptor and enhances synaptic plasticity to restore normal neural cell function. This mechanism is distinct from those of any other therapies, emerging or marketed, for neuropathic pain.
Aptinyx is currently conducting a Phase 2 study of NYX-2925 in patients with neuropathic pain associated with diabetic peripheral neuropathy (DPN), as well as an exploratory study in patients with fibromyalgia. The U.S. Food and Drug Administration has granted Fast Track designation to Aptinyx's development of NYX-2925 for the treatment of neuropathic pain associated with DPN.
Preclinical Through Early-Stage Clinical Development of a Novel NMDA Receptor Modulator, NYX-2925 (Poster # 15)
Presenter: David R. Houck, Ph.D., Vice President, Drug Development Operations, Aptinyx
Poster Session: 3:45 p.m. to 5:30 p.m. ET on Thursday, March 8, 2018
Presentation Time: 2:10 p.m. to 2:20 p.m. ET on Thursday March 8, 2018